Improving Profitability A Key Mid-Term Focus For Takeda
CEO Christophe Weber remains resolutely upbeat on the progress of Takeda's strategic transformation plan, the dividends of which he said are apparent in the leading Japanese pharma firm's fiscal year performance.
You may also be interested in...
Takeda will pay $5.2bn to buy Ariad Pharmaceuticals, the developer of one marketed cancer therapy, Iclusig – but the latter firm's US location and operations could be other important draws for the Japanese big pharma, which has previously announced plans to overhaul its own R&D activities.
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.